Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system (“CNS”) diseases resulting from BAG3 gene variants, today announced the appointment of Marc Semigran, M.D., as chief medical officer of Renovacor.

Biotechnology

Renovacor

Magdalene Cook

Wendy DiCicco

Kumar Dhanasekharan

Marc Semigran

Jiwen Zhang

Matt Killeen

Beth White

Directors

Leadership Team

Scientific Advisory Team

Teams at Renovacor

Directors

Leadership Team

Scientific Advisory Team